The Shotlee Journal
Browse Shotlee articles about Retatrutide.
Showing 9 / 60 Retatrutide articles
Retatrutide is exploding on TikTok among gym enthusiasts for its potent weight loss effects, but it's not FDA-approved yet. This guide breaks down its triple-hormone mechanism, compares it to semaglutide and tirzepatide, and warns of black market risks. Learn why experts urge caution.
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
Weight loss medications such as Wegovy and Zepbound are set to become more accessible and affordable, moving beyond high costs and weekly shots. New pill forms offer alternatives for those avoiding injections, with significant developments in GLP-1 treatments expected. Advances in pricing and access programs aim to broaden availability for patients.
The bodybuilding scene has seen major changes lately, especially with the rise of SARMs as steroid alternatives. These substances target muscle and bone for better performance, but users must weigh the benefits against possible health issues. Ongoing research highlights their therapeutic uses and the importance of responsible consumption.
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
Eli Lilly & Co. is experiencing heightened market interest, fueled by significant institutional investor activity and promising clinical data. The convergence of these factors raises questions about the sustainability of the company's valuation in light of high expectations.
A new weight loss drug, retatrutide, is showing promise by mimicking three hunger-regulating hormones. Clinical trial data indicates significant weight loss and reduced knee pain.
A novel drug candidate from Eli Lilly, targeting three metabolic pathways, has shown impressive weight loss results in a late-stage clinical trial. The study revealed an average weight loss of 28.7% among participants. However, the trial also reported a notable rate of treatment discontinuation.
